7 July, 2021

EPO communicates intention to grant Nanexa’s PharmaShell® patent in Europe

Nanexa AB is pleased to announce that the European Patent Office (EPO) has today issued a communication advising that it intends to grant a European patent relating to Nanexa’s PharmaShell® technology.

7 July, 2021

Nanexa raises approximately SEK 126.7 million in fully subscribed rights issue

Nanexa AB (publ) (”Nanexa” or the “Company”) today announces that the new share issue with preferential rights for the Company’s existing shareholders of approximately SEK 126.7 million before transaction costs (the “Rights Issue”) was fully subscribed. Approximately 16.6 percent of the Rights Issue was subscribed for through subscription commitments. In addition to the subscription through subscription commitments, approximately 40.2 percent was subscribed for by the use of subscription rights, and approximately 14.9 percent was subscribed for without subscription rights. The remaining part of the Rights Issue was subscribed for through guarantee commitments from the existing shareholder Rutger Arnhult via M2 Capital Management, and from external investors, including, amongst others, Health Runner and Modelio Equity.


28 juni, 2021

Redeye analytiker-intervju med vd David Westberg

17 juni, 2021

Webcast och frågestund


Meet Nanexa

  • No scheduled meetings